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OBJECTIVES The goal of this study was to evaluate the utility of a rapid “bedside” technique for
measurement of B-type natriuretic peptide (BNP) in the diagnosis of congestive heart failure
(CHF) in an urgent-care setting.
BACKGROUND B-type natriuretic peptide is a protein secreted from the cardiac ventricles in response to
pressure overload. One potential application of measurements of BNP in blood is distin-
guishing dyspnea due to CHF from other causes.
METHODS B-type natriuretic peptide concentrations were measured in a convenience sample of 250
predominantly male (94%) patients presenting to urgent-care and emergency departments of
an academic Veteran’s Affairs hospital with dyspnea. Results were withheld from clinicians.
Two cardiologists retrospectively reviewed clinical data (blinded to BNP measurements) and
reached a consensus opinion on the cause of the patient’s symptoms. This gold standard was
used to evaluate the diagnostic performance of the BNP test.
RESULTS The mean BNP concentration in the blood of patients with CHF (n 5 97) was higher than
it was in patients without (1,076 6 138 pg/ml vs. 38 6 4 pg/ml, p , 0.001). At a blood
concentration of 80 pg/ml, BNP was an accurate predictor of the presence of CHF (95%);
measurements less than this had a high negative predictive value (98%). The overall
C-statistic was 0.97. In multivariate analysis, BNP measurements added significant, inde-
pendent explanatory power to other clinical variables in models predicting which patients had
CHF. The availability of BNP measurements could have potentially corrected 29 of the 30
diagnoses missed by urgent-care physicians.
CONCLUSIONS B-type natriuretic peptide blood concentration measurement appears to be a sensitive and
specific test to diagnose CHF in urgent-care settings. (J Am Coll Cardiol 2001;37:379–85)
© 2001 by the American College of Cardiology
Differentiating congestive heart failure (CHF) from other
causes of dyspnea is of extreme importance in patients
presenting to the emergency department with acute short-
ness of breath. But symptoms and physical exam findings
are not sensitive enough to make an accurate diagnosis (1),
and, although echocardiography is considered the gold
standard for detecting left ventricular (LV) dysfunction, it is
expensive, not easily accessible and may not always reflect an
acute condition (2). Currently, no blood test can differen-
tiate a patient with heart failure from a patient without heart
failure (3).
B-type natriuretic peptide (BNP) is a cardiac neurohor-
mone secreted from the cardiac ventricles as a response to
ventricular volume expansion and pressure overload (4,5).
B-type natriuretic peptide levels have been shown to be
elevated in patients with LV dysfunction and correlate to
New York Heart Association class as well as prognosis (6,7).
Although plasma BNP appears to be stable in whole blood
and relatively straightforward to assay, until recently its
utility as a diagnostic aid in the urgent-care setting has been
limited by protracted assay time (8).
Using a rapid (15 min), point-of-care test for BNP
(Biosite Diagnostics, San Diego, California), we sought to
determine if BNP levels could have an impact on the
diagnosis of CHF in the urgent-care setting.
METHODS
Study population. The study was approved by the Univer-
sity of California’s Institutional Review Board. A conve-
nience sample of 250 patients presenting to the urgent-care
area of the San Diego Veteran’s Health Care System with
symptoms of dyspnea were recruited in June and October
1999. Eligibility included shortness of breath as a prominent
complaint. Associated symptoms could be edema, weight
gain, cough or wheezing. Patients whose dyspnea was
clearly not secondary to CHF (trauma or cardiac tampon-
ade) were excluded. Patients with acute coronary syndromes
were excluded unless their predominant presentation was
CHF.
A review of medical billing forms from the recruitment
period found that 438 patients with relevant medical diag-
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noses were treated during the study (Internal Classification
of Disease Revision 9 codes of 428.09 [CHF], 428.1 [left
heart failure], 496 [chronic airway obstruction], 782
[edema], 786.05 [shortness of breath] or 786.09 [dyspnea]).
The rate of refusal of patients approached for entry was
,5%.
Once consent was obtained, other data was recorded,
including elements from the history, physical exam, reports
of blood tests and interpretations of chest X-rays or other
diagnostic tests. Echocardiograms were strongly encour-
aged, either in the emergency department, as an outpatient
or in the hospital if the patient was admitted.
Physicians assigned to the emergency department (special-
ists or general medicine internists) were asked to make an
assessment of the probability of the patient having CHF (low,
medium and high) as the cause of his or her symptoms and
were blinded to the results of BNP measurements. If a patient
had a history of CHF noted, physicians would classify the
patient as having either an acute exacerbation of CHF or low
probability CHF, with underlying LV dysfunction (i.e., some-
one with LV dysfunction but seen for bronchitis).
Confirmation of the diagnosis. To determine patients
actual diagnosis, two cardiologists reviewed all medical
records pertaining to the patient and made independent
initial assessments of the probability of each patient having
CHF (high or low or low plus baseline LV dysfunction) and
were blinded to the patient’s BNP level. While blinded to
the emergency department physicians’ diagnosis, cardiolo-
gists had access to the emergency department data sheets as
well as to any additional information that later became
available. This might include: official reading of chest X-ray,
past history not available at the time for the emergency
department physicians, the results of subsequent tests to
measure systolic or diastolic function and, finally, the
hospital course for patients admitted to the hospital. Con-
firmation of high-probability CHF was based on generally
accepted Framingham criteria ([9] with corroborative infor-
mation including hospital course [response to diuretics,
vasodilators, inotropes or hemodynamic monitoring]) and
results of further cardiac testing. For patients with a
diagnosis other than CHF, confirmation was attempted
using the following variables: normal chest X-ray (lack of
heart enlargement and pulmonary venous hypertension);
X-ray signs of chronic obstructive lung disease, pneumonia
or lung cancer; normal heart function by echocardiography,
nuclear medicine ejection fractions or left ventriculography
done at cardiac catheterization; abnormal pulmonary func-
tion tests or follow-up in pulmonary clinic; response to
treatment in the emergency department or hospital with
nebulizers, steroids or antibiotics; no CHF admissions over
the next 30 days. In the cases where cardiologists disagreed
on the diagnosis or severity of CHF, further tests were
ordered until a consensus was reached.
Measurement of BNP plasma levels. During initial eval-
uations, a small sample (5 cc’s) was collected into tubes
containing potassium EDTA (1 mg/ml blood). B-type
natriuretic peptide was measured using the Triage B-Type
Natriuretic Peptide test (Biosite Diagnostics Inc., San
Diego, California). The Triage BNP Test is a fluorescence
immunoassay for the quantitative determination of BNP in
whole blood and plasma specimens. After addition of the
blood sample to the sample port of the test device, the red
blood cells were separated from the plasma via a filter. A
predetermined quantity of plasma moves by capillary action
into a reaction chamber to form a reaction mixture. After
the incubation period, the reaction mixture flows through
the device detection lane. Complexes of BNP and fluores-
cent antibody conjugates are captured on a discrete zone in
the detection lane. Excess plasma sample washes the un-
bound fluorescent antibody conjugates from the detection
lane into a waste reservoir. The concentration of BNP in the
specimen is proportional to the fluorescence bound in the
detection lane and was quantified by the portable triage
meter. When possible, BNP levels were measured in whole
blood and processed within 4 h. When this was not possible,
samples were spun down, and the plasma was frozen until
the sample was analyzed (one to two days later), an
approach known to produce well-calibrated results with
whole blood sample methods.
Statistics. Group comparisons of BNP values were made
using t tests for independent samples and analyses of
variance. Log-transformed BNP values were used in all
analyses to reduce effects from skewness in the distribution
of BNP concentrations.
To evaluate the utility of BNP measurements in the
diagnosis of CHF, we compared the sensitivity, specificity
and accuracy of BNP measurements to individual findings,
to a multivariate model of clinical findings and to clinical
judgment. For each of the different clinical and X-ray
findings identified by emergency department physicians and
different threshold BNP concentrations, we computed sen-
sitivity, specificity and accuracy. Then, to determine if BNP
measurements added independent diagnostic information to
commonly collected clinical variables, we applied multivar-
iate stepwise logistic regression. We developed the best
predictive model based on historical, clinical and X-ray
findings, using a p value $0.1 for entry into the model.
After a stable model was obtained, we added BNP mea-
surements to the predictive model and assessed improve-
ment in the degree of fit. To determine if BNP measure-
ments could improve the diagnostic performance of
emergency department clinicians, we compared receiver
curves for various BNP cutoff concentrations with the
emergency department clinician’s diagnosis.
Abbreviations and Acronyms
ANP 5 atrial natriuretic peptide
BNP 5 B-type natriuretic peptide
CHF 5 congestive heart failure
LV 5 left ventricle, left ventricular
NPV 5 negative predictive value
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RESULTS
The characteristics of the 250 patients are shown in Table 1.
Fifty percent of patients had acute shortness of breath at rest
as a presenting complaint.
Final cardiology assessment revealed that ninety-seven
patients (39%) had acute CHF as a cause of their dyspnea,
while fourteen patients (6%) had baseline LV dysfunction
with no acute exacerbation of their heart failure. The
remaining 139 (55%) had a cause other than CHF for their
dyspnea.
Association of BNP levels with diagnosis, severity, phys-
ical examination findings and disposition. Figure 1 pre-
sents a box plot of log BNP values with means and standard
errors for the “no CHF” and the “CHF” groups. The group
difference was significant (p , 0.001). Patients diagnosed
with CHF (n 5 97) had a mean BNP concentration of
1,076 6 138 pg/ml while the non-CHF group (n 5 139)
had a mean BNP concentration of 38 6 4 pg/ml. The group
of 14 identified as baseline ventricular dysfunction without
an acute exacerbation had a mean concentration of 141 6
31 pg/ml.
Figure 2 shows BNP values in relation to CHF severity,
admission versus no admission from the emergency depart-
ment, pulmonary disease and pedal edema. Median BNP
concentrations increased as the assessed severity of disease
increased (Fig. 2A, p , 0.001 for differences between
groups). B-type natriuretic peptide concentrations were
higher for patients admitted to the hospital versus dis-
charged patients (700 6 116 pg/ml vs. 254 6 60 pg/ml, p ,
0.001; Fig. 2B). Patients with a final diagnosis of pulmonary
disease without underlying heart dysfunction (Fig. 2C) had
lower BNP values (86 6 39 pg/ml) than those with a final
diagnosis of CHF (1,076 6 138 pg/ml, p , 0.001). Finally,
mean BNP concentrations were higher for patients with
pedal edema secondary to CHF (1,038 6 163 pg/ml, Fig.
2D) than those with pedal edema due to non-CHF causes
(63 6 16 pg/ml, p , 0.001).
Association between BNP levels and final diagnosis.
Univariate analysis was performed for all variables pertinent
to a diagnosis of CHF, along with BNP concentrations at
80, 100, 115, 120 and 150 pg/ml. The sensitivity, specificity
and accuracy for each variable is reported in Table 2. The
best clinical predictor was a past history of CHF (81%
accuracy) followed by heart size on chest X-ray (75%
accuracy). B-type natriuretic peptide was an accurate pre-
dictor of patient diagnosis. Accuracy appeared to be optimal
at a concentration of 80 pg/ml.
In multivariate analyses, we evaluated the combined
explanatory power of history, symptoms, signs, radiological
studies and lab findings (Table 3). Addition of BNP levels
to the regression substantially increased the explanatory
power of the model, suggesting that BNP measurements
provided meaningful diagnostic information not available
from other clinical variables.
A receiver operating characteristic curve, shown in Figure
3, shows the sensitivity and specificity of BNP measure-
ments and compares this to the treating physician’s judg-
ment. Although the treating physicians performed well
(C-statistic of 0.884), BNP concentration measurements
appeared to have better overall performance (C-statistic of
0.979). In the subgroup of patients without a prior history of
CHF, BNP again gave a better overall performance than
treating physicians (C-statistic of 0.94).
Fifteen patients were diagnosed as having CHF by the











Shortness of breath at rest 50%
Dyspnea on exertion 70%
Orthopnea 26%







Systolic blood pressure .149 28%
S3 8%
S4 5%
CAD 5 coronary artery disease; CHF 5 congestive heart failure; COPD 5 chronic
obstructive pulmonary disease; JVP 5 jugular venous pressure.
Figure 1. B-type natriuretic peptide levels of patients diagnosed with
CHF, baseline left ventricular dysfunction and without CHF. BNP 5
B-type natriuretic peptide; CHF 5 congestive heart failure.
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emergency department physicians when they actually had
other causes of their dyspnea. The mean BNP level in this
group was 46 6 13 pg/ml. Fifteen patients with the ultimate
diagnosis of CHF were not diagnosed correctly at the time
of their visit. In this group, the mean BNP was 742 6
337 pg/ml. If a cutoff value of 80 pg/ml had been utilized,
twenty-nine of thirty misdiagnosed cases would have been
corrected.
DISCUSSION
Difficulty in the emergency department diagnosis of
heart failure. Because patients with LV dysfunction have
improved survival and increased well-being on medications
such as angiotensin-converting enzyme inhibitors and beta-
adrenergic blocking agents (10), it is imperative to make a
correct diagnosis. For the acutely ill patient presenting to
the emergency department, a misdiagnosis could place the
patient at risk for both morbidity and mortality (11).
Therefore, the emergency department diagnosis of CHF
needs to be rapid and accurate.
Unfortunately, the signs and symptoms of CHF are
nonspecific (1). A helpful history is not often obtainable in
an acutely ill patient, and dyspnea, a key symptom of CHF,
may be a nonspecific finding in the elderly or obese patient
in whom comorbidity with respiratory disease and physical
deconditioning are common (2). Routine lab values, elec-
trocardiograms and X-rays are also not accurate enough to
always make the appropriate diagnosis (1,12). Thus, it is
difficult for clinicians to differentiate patients with CHF
from other diseases, such as pulmonary disease, on the basis
of routinely available laboratory tests.
Echocardiography, although currently the gold standard
in diagnosing LV dysfunction, is costly and has limited
availability in urgent-care settings. Dyspneic patients may
be unable to hold still long enough for an echocardiographic
study, and others may be difficult to image secondary to
comorbid factors such as obesity or lung disease. Therefore,
even in settings where emergency department echocardiog-
raphy is available, an accurate, sensitive and specific blood
test for heart failure would be a useful addition to the
clinical armamentarium.
BNP. B-type natriuretic peptide is a 32-aa polypeptide con-
taining a 17-aa ring structure common to all natriuretic
peptides (13). The source of plasma BNP is cardiac ventricles,
which suggests that it may be a more specific indicator of
ventricular disorders than other natriuretic peptides (3–5,14).
The nucleic acid sequence of the BNP gene contains the
destabilizing sequence “tatttat,” which suggests that turnover of
BNP messenger RNA is high and that BNP is synthesized in
bursts (4,15). This release appears to be directly proportional to
Figure 2. (A) BNP concentrations for the degree of CHF severity. (B) Hospital admission versus BNP. (C) BNP levels in patients with dyspnea secondary
to CHF or chronic obstructive lung disease. (D) BNP levels in patients with edema diagnosed with CHF or non-CHF. Boxes represent mean and
interquartile range. Vertical line without a dot represents a range from 10% to 90%. A dot with a line represents the mean and SEM. Values shown
represent the mean (SEM). BNP 5 B-type natriuretic peptide; CHF 5 congestive heart failure; Dx 5 diagnosis.
382 Dao et al. JACC Vol. 37, No. 2, 2001
BNP Utility in Acute CHF Diagnosis February 2001:379–85
ventricular volume expansion and pressure overload (4–7,16).
B-type natriuretic peptide is an independent predictor of high
LV end-diastolic pressure (6) and correlates to New York
Heart Association classification (7).
BNP as a screen of CHF. B-type natriuretic peptide has
been used to a limited extent as a screening procedure in
primary care settings and in this venue has been shown to be
a useful addition in the evaluation of possible CHF (17–20).
In a community-based study where 1,653 subjects under-
went cardiac screening, the negative predictive value of BNP
of 18 pg/ml was 97% for LV systolic dysfunction (19). In a
study of 122 consecutive patients with suspected new heart
failure referred by general practitioners to a rapid-access
heart failure clinic for diagnostic confirmation, a BNP level
of 76 pg/ml, chosen for its negative predictive value of 98%
for heart failure and similar to the cutoff in the present
study, had a sensitivity of 97%, a specificity of 84% and a
positive predictive value of 70% (17). Finally, Davis et al.
(20) measured the natriuretic hormones atrial natriuretic
peptide (ANP) and BNP in 52 patients presenting with
acute dyspnea and found that admission plasma BNP
concentrations more accurately reflected the final diagnosis
than did ejection fraction or concentration of plasma ANP.
Point-of-care testing of BNP in the urgent-care setting.
Perhaps the reason BNP has not been used more often
is that, until recently, the assay for BNP has been difficult
to perform and is time-consuming. The assay used in this
study is available in a form that could allow rapid de-
termination of BNP levels at the point of care and, thus,
could make a substantial difference in the management of
patients presenting to the emergency department with
dyspnea.
For diagnostic screening tests to be useful in an urgent-
care setting, they should have a high negative predictive
value (NPV), allowing clinicians to rapidly rule out serious
disorders (21) and facilitate efficient use of valuable re-
sources. In the population studied, a BNP of ,80 pg/ml
had a NPV of 98%, which would allow clinicians to exclude











CHF 62 (52–71) 94 (88–97) 87 (77–93) 78 (71–84) 80
MI 38 (29–48) 78 (71–85) 55 (43–67) 64 (57–71) 62
HTN 46 (34–59) 55 (47–63) 34 (24–44) 68 (58–76) 52
COPD 34 (25–44) 63 (54–70) 39 (29–50) 58 (49–65) 51
DM 40 (31–51) 81 (74–87) 60 (47–72) 66 (59–73) 64
Symptoms
Dyspnea 56 (45–66) 53 (45–62) 45 (36–55) 63 (54–72) 54
Dyspnea on exertion 81 (72–88) 37 (29–45) 47 (40–55) 74 (62–83) 55
Orthopnea 47 (37–58) 88 (82–93) 74 (61–84) 71 (63–77) 72
Paroxysmal nocturnal dypsnea 38 (29–48) 81 (74–87) 59 (46–71) 65 (58–72) 64
Cough 42 (33–53) 60 (51–68) 42 (33–53) 60 (51–68) 53
Edema 67 (57–76) 68 (60–76) 60 (50–69) 75 (66–82) 68
Signs
SB . 149 28 (20–39) 73 (65–80) 42 (30–54) 59 (51–66) 54
SB , 100 6 (3–13) 97 (93–99) 60 (21–93) 60 (53–66) 60
JVP elevated 39 (30–50) 94 (88–97) 81 (67–90) 69 (62–75) 72
Rales 56 (45–66) 80 (72–86) 66 (55–76) 72 (64–79) 70
Wheezing 23 (15–32) 68 (60–76) 33 (23–46) 56 (48–63) 50
Ascites 1 (0–6) 97 (93–99) 20 (19–85) 58 (52–65) 58
S3 20 (13–29) 99 (95–100) 90 (69–100) 64 (57–70) 66
S4 7 (3–14) 96 (92–99) 58 (24–88) 60 (53–66) 60
Murmurs 32 (23–42) 90 (84–94) 69 (53–82) 66 (58–72) 66
Chest x-ray and ECG
Heart size 88 (75–95) 72 (65–78) 45 (35–56) 96 (91–98) 75
PVH 41 (32–52) 96 (91–98) 87 (74–95) 70 (63–76) 73
ST elevation 6 (3–13) 97 (98–99) 60 (21–93) 60 (53–66) 60
ST depression 12 (7–21) 93 (87–96) 55 (31–76) 60 (53–67) 60
Afib 8 (4–16) 99 (96–100) 89 (48–107) 61 (54–67) 62
BNP levels (pg/ml)
80 98 (93–100) 92 (86–96) 90 (82–94) 98 (94–100) 95
100 94 (89–97) 94 (89–97) 92 (85–96) 96 (91–98) 94
115 90 (83–95) 96 (91–98) 94 (87–97) 94 (88–97) 94
120 90 (82–95) 96 (92–99) 95 (88–98) 93 (88–96) 94
150 87 (78–92) 97 (93–99) 95 (89–98) 91 (85–95) 93
Afib 5 atrial fibrillation; BNP 5 B-type natriuretic peptide; CHF 5 congestive heart failure; COPD 5 chronic obstructive pulmonary disease; DM 5 diabetes mellitus; ECG 5
electrocardiogram; HTN 5 hypertension; MI 5 myocardial infarction; PVH 5 pulmonary venous hypertension; SB 5 systolic blood pressure.
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CHF as a cause of symptoms in most circumstances. No
single clinical finding had similar sensitivity, specificity and
accuracy. And in multivariate analyses, BNP measurements
added independent explanatory power when added to mod-
els predicting the presence of CHF from the best combi-
nation of clinical variables.
Study limitations. This is an observational study per-
formed in a convenience sample of predominantly male
patients at a Veteran’s Affairs Medical Center. These factors
limit generalizability of results observed in this study. As is
often true with diagnostic tests, the performance of BNP
measurements in other populations may not equal the
performance seen in this initial study. A multicenter, inter-
national trial is underway (Breathing Not Proper in CHF)
in attempt to further elucidate and confirm our findings in
broader populations.
Conclusions. The measurement of the BNP concentration
in blood appears to be a sensitive and specific test for the
Table 3. Multivariate Analysis Using All Significant Variables With BNP Analyzed Last for All 250 Cases and for Cases Where









History of CHF 89.01 0 62 93 80
Heart size 31.96 0 77 91 85
Murmurs 19.24 0 77 91 85
Pulmonary venous hypertension 11.9 0.006 78 91 86
ECG—atrial fibrillation 9.06 0.0026 80 91 86
Pedal edema 9.96 0.0016 89 89 89
Orthopnea 6.37 0.0116 80 91 86
ECG—ST depression 4.46 0.0346 82 91 87
History of diabetes mellitus 4.32 0.0377 85 90 88
BNP 95.23 0 96 96 97
Cases without history of CHF
Pulmonary venous hypertension 32.48 0 41 97 84
Murmurs 26.48 0 76 87 84
Jugular venous distension 11.71 0.006 51 97 87
ECG—atrial fibrillation 12.54 0.0004 49 98 87
ST depression 6.26 0.0124 57 98 89
ECG—T wave inversion 6.09 0.0136 68 97 90
Dyspnea on exertion 5.62 0.0178 81 92 90
History of angina 4.95 0.026 73 97 92
BNP 55.27 0 95 100 98
BNP 5 B-type natriuretic peptide; CHF 5 congestive heart failure; ECG 5 electrocardiogram.
Figure 3. Receiver operating characteristic curves of BNP and emergency department diagnosis using all 250 patients. AUC 5 area under the curve; BNP 5
B-type natriuretic peptide; ER 5 emergency room.
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identification of patients with CHF in urgent-care settings.
If the results of this study are borne out in subsequent ones,
this test may replace chest X-ray (and perhaps even echo-
cardiography) as the test of choice in differential diagnosis of
dyspnea in urgent-care settings. At the minimum, it is likely
to be a potent, cost-effective addition to the diagnostic
armamentarium of urgent-care physicians.
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